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Abstract
Background: Enzyme replacement therapy (ERT) with α-galactosidase A (α-Gal A) is currently the most effective 
therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short 
half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we 
investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry 
disease mouse model and compared it with that of ERT.
Methods: A pseudotyped rAAV2/8 vector encoding α-Gal A cDNA (rAAV2/8-hAGA) was prepared and injected into 18-
week-old male Fabry mice through the tail vein. The α-Gal A expression level and globotriaosylceramide (Gb3) levels in 
the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural 
studies were conducted.
Results: Treatment of Fabry mice with rAAV2/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as 
liver, spleen, kidney, heart, and brain with concomitant elevation of α-Gal A enzyme activity. Enzyme activity was 
elevated for up to 60 weeks. In addition, expression of the α-Gal A protein was identified in the presence of rAAV2/8-
hAGA at 6, 12, and 24 weeks after treatment. α-Gal A activity was significantly higher in the mice treated with rAAV2/8-
hAGA than in Fabry mice that received ERT. Along with higher α-Gal A activity in the kidney of the Fabry mice treated 
with gene therapy, immunohistochemical studies showed more α-Gal A expression in the proximal tubules and 
glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The α-gal A 
gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron 
microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT.
Conclusions: The rAAV2/8-hAGA mediated α-Gal A gene therapy provided improved efficiency over ERT in the Fabry 
disease mouse model. Furthermore, rAAV2/8-hAGA-mediated expression showed a greater effect in the kidney than 
ERT.
Background
Fabry disease (OMIM #301500) is an X-linked inborn
error of glycosphingolipid metabolism that is caused by a
deficiency of α-galactosidase A (α-Gal A) [1]. The lack of
this enzyme leads to the progressive accumulation of gly-
cosphingolipids, such as globotriaosylceramide (Gb3) in
lysosomes. Gb3 accumulates mainly in the endothelial
cells of the kidney, heart, liver, and spleen, as well as in
the plasma, and causes diseases such as angiokeratomas,
hypohidrosis, stroke, cardiac, and renal failure [2-4].
Enzyme replacement therapy (ERT) with α-Gal A has
been developed to treat Fabry disease. Two forms of the
enzyme are available: agalsidase alfa and agalsidase beta.
Agalsidase alfa (Replagal; Shire Human Genetic Thera-
pies, Cambridge, MA, USA) is produced in a continuous
human cell line by gene activation and is used at a dose of
0.2 mg/kg infused intravenously every other week (EOW)
[5]. Agalsidase beta (Fabrazyme; Genzyme, Cambridge,
MA, USA) is produced in chinese hamster ovary cells and
is intravenously administered at a dose of 1.0 mg/kg
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EOW [6]. These two forms share the same amino acid
sequence but have different glycosylation patterns, most
likely because of the different manufacturing methods
[7]. Clinical trials in adults using both forms of the
enzyme have produced biochemical and clinical evidence
for their efficacy [6,8,9].
However, potential limitations include the absence of
long-term effects using this approach, possible immuno-
logical consequences, inevasible progression of renal fail-
ure that is impossible to recover, low cost-effectiveness,
and overall inconvenience of this treatment as a result of
the requirement for continued administration of large
doses of enzyme necessary for therapy. Therefore, gene
therapy for Fabry disease has been explored using a vari-
ety of viral vector delivery systems [10-13]. These gene
therapy studies appear to be effective in the Fabry disease
mouse model. Among them, a recent gene therapy study
using pseudotyped recombinant adeno-associated virus
(rAAV) vector showed very promising results [13].
Although the gene therapy studies should have better
efficacy and do not have the safety issues compared with
clinical use of ERT, there is no report regarding a compar-
ison study of gene therapy and ERT.
In the present study, we investigated pseudotyped
rAAV2/8-mediated gene delivery of α-Gal A and com-
pared the efficacy of gene therapy with that of ERT. The
AAV serotype 8 capsid was selected because it has shown
to transduce mouse hepatocytes better than the AAV
serotype 2 [13,14]. Furthermore, comparison of the effi-
cacy of gene therapy and ERT in Fabry mice has focused
on their affect on renal pathology, where ERT has been
shown to cause the most derangement [9,15].
Methods
Animals
A pair of Fabry mice, which were kindly provided by Dr.
Roscoe O. Brady of the National Institutes of Health
(Bethesda, MD, USA), were bred to acquire a sufficient
number of mice for the study [16]. The mice were 18
weeks old at the beginning of the study. All mice were
genotyped by polymerase chain reaction (PCR), as
described previously [16]. A minimum of three age-
matched animals was used for each group. The mice were
fed an autoclaved diet and water ad libitum. All animals
were treated in accordance with the Animal Care Guide-
lines of the Ewha Womans University School of Medicine
(Seoul, Korea). For enzyme replacement therapy, the
Fabry mice received an infusion of 1.0 mg/kg body weight
of recombinant α-galactosidase A (Genzyme) in normal
saline via the tail vein once a week for 6 consecutive
weeks [17]. The mice were killed and their tissues were
analyzed one week after the last enzyme infusion. The
rAAV 2/8-hAGA vector was delivered by intravenous
administration via the tail vein of the mice. Blood samples
were collected from the tail vein every other week.
Preparation of rAAV-hAGA viral vectors
The AAV serotype 2-based human α-galactosidase A
cDNA containing plasmid harboring the human elonga-
tion factor 1-α promoter and the rep2/cap2 or rep2/cap8
plasmids, kindly provided by James M. Wilson, were used
to package the expression vector [14]. The rAAV2/2-
hAGA and rAAV2/8-hAGA vectors were produced using
the triple plasmid transfection method, and purified on a
cesium chloride (Sigma-Aldrich, St. Louis, MO, USA)
density gradient [12]. The rAAV genomic titer was deter-
mined by real-time quantitative PCR using an ABI 7700
TaqMan sequence detection system (PerkinElmer
Applied Biosystems, Foster City, CA, USA).
α-Gal A enzyme activity assay
A fluorimetric assay for α-Gal A was performed as
described previously [18] with minor modifications. The
tissue samples were homogenized and sonicated in an
aqueous buffer containing 5 mg/ml sodium taurocholate,
pH 4.4, and centrifuged at 20,000 × g for 30 min. The α-
Gal A activity was determined by incubating aliquots of
the supernatant at 37°C in a pH 4.4 buffer containing 28
mM citric acid, 44 mM disodium phosphate, 5 mM 4-
methylumbelliferyl-α-D-galactopyranoside, 4 mg/ml
bovine serum albumin and 0.1 M N-acetyl-galac-
tosamine, a specific N-acetylgalactosaminidase inhibitor.
Quantitation of Gb3 levels
Extraction and saponification of lipids, and extraction of
the glycolytic fraction were performed as described pre-
viously [19]. The glycolipid fraction was mixed with 5 ml
of N-acetyl-galactosylsphingosine and 795 μl of 80% diox-
ane and then analyzed using a liquid chromatography-
mass/mass spectrometer system (LC-MS/MS, ABI 4000;
Applied Biosystems, Foster City, CA, USA). Quantitation
of glycolipids was performed using a C8 Column and an
evaporative light-scattering detector. The Gb3 standard
was obtained from Matreya (Pleasant Gap, PA, USA).
Polymerase chain reaction for the determination of viral 
vector distribution
Genomic DNA was extracted from livers, kidneys, hearts,
spleens, and brains using lysis buffer (100 mM Tris-HCl,
5 mM EDTA, 0.2% SDS, 200 mM NaCl) according to the
manufacturer's instructions. Genomic DNA (0.5 μg)
using primers and a Power DNA Synthesis Kit (Intron
Biotechnology, Seongnam, Korea). PCR amplification
was conducted in 20 μl of PCR buffer (50 mM KCl in 10
mM Tris-HCl, pH 9.0 containing 0.1% Triton X; Pro-
mega, Madison, WI, USA) containing 0.5 μg of template
DNA, 5 μM each of the primers, 0.2 mM dNTP, and 2.5Choi et al. Journal of Biomedical Science 2010, 17:26
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units of Taq polymerase, for 25 cycles at 94°C for 40 s, at
58°C for 30 s, and at 72°C for 1 min.
Western blot analysis
Tissue samples (100 mg) that were stored in liquid nitro-
gen were homogenized in a Pro-Prep solution (Intron
Biotechnology, Seongnam, Korea). The tissue lysate was
centrifuged at 13,000 × g for 30 min, and the supernatant
was collected and heated at 100°C for 5 min. Equal
amounts of the protein were separated by 8%-12% SDS-
PAGE and transferred to a polyvinylidene difluoride
membrane (Millipore, Bedford, MA, USA). The mem-
branes were blocked with 5% skim milk in TBST (20 mM
Tris-HCl, pH 7.5; 500 mM NaCl; and 0.1% Tween-20) for
2 h at room temperature, and incubated sequentially with
the primary antibodies, polyclonal anti-rabbit GLA (α-
Gal A) antibody (Santa Cruz Biotechnology, San Diego,
CA, USA), or glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) antibody (Sigma-Aldrich). The mem-
branes were washed and incubated with the HRP-
conjugated secondary anti-rabbit antibodies (Santa Cruz
Biotechnology). The washes were repeated two times and
the membranes were developed using a chemilumines-
cent agent (ECL; GE Healthcare, Buckinghamshire, UK)
and visualized using a Bio-Imaging analyzer (LAS-3000;
Fuji, Tokyo, Japan). The relative protein expression level
of the individual genes for each sample was normalized
against GAPDH expression.
Immunohistochemical staining of α-Gal A
The excised tissues were fixed for 24 h in PBS containing
4% paraformaldehyde at 4°C and embedded in paraffin.
The sections (4 μm thick) were mounted on silane-coated
slides (Muto Pure Chemicals, Tokyo, Japan) and incu-
bated with anti-α-Gal A rabbit antibody (Sigma-Atlas,
Stockholm, Sweden) visualized using a Vectastain ABC
kit method (Vector Laboratories, Burlingame, CA, USA).
The slides were counterstained with hematoxylin and
examined using an optical microscope (BH60; Olympus,
Tokyo, Japan).
Immunostaining of Gb3
Mice were anesthetized with ether and perfused through
the heart with 0.05 M phosphate buffered saline (PBS),
followed by 4% paraformaldehyde (in 0.1 M phosphate
buffer). Their kidneys were fixed for 30 min in 4% para-
formaldehyde, cryoprotected by infiltration with increas-
ing concentrations of sucrose (10%-30%), and frozen in
freezing medium. Kidneys were cut into 5 μm thick sec-
tions on a cryostat (CM 3000; Leica Microsystems, Wet-
zlar, Germany) and collected on gelatin-coated slides.
The tissue sections were rinsed in PBS and then
immersed in 0.3% hydrogen peroxide (in PBS) for 30 min
at room temperature. They were preincubated in 10%
normal horse serum (Vector Laboratories) for 1 h and
subsequently incubated in rat anti-CD77/Gb3 antiserum
(1:200, Chemicon, Temecula, CA, USA) overnight at 4°C.
A second incubation with HRP-conjugated anti-rat IgG
(1:1000, Vector Laboratories) was performed for 1 h at
room temperature. The slides were counterstained with
hematoxylin and examined using an optical microscope
(BH60; Olympus).
Ultrastructural study
Mice were killed after 6 weeks of infection with the viral
vector. Kidneys were removed and fixed in 10% neutral
buffered formalin, methyl Carnoy's solution. For electron
microscopy (EM), small blocks of tissues were fixed with
2.5% glutaraldehyde and 2% paraformaldehyde, followed
by postfixation in 1% osmium tetroxide, and embedded in
Epon using a standard procedure. Epon-embedded
blocks were cut at 80 nm with a diamond knife. The ultra-
thin sections were double-stained with uranyl acetate and
lead citrate for electron microscopy. The same block faces
were cut at 1 μm with a sapphire knife replacing a dia-
mond knife. These semithin sections were fixed onto
lysine-coated slide glasses laying on a hot plate at 60 to
70°C. Ultrathin sections were prepared using a Leica
ultratome (Reichert Ultracuts, Wien, Austria) and stained
with 4% uranyl acetate for 45 min, and subsequently with
lead citrate for 4 min at room temperature. Sections were
examined in an H-7650 electron microscope (Hitachi,
Ibaraki-ken, Japan).
Liver function test
Hepatic toxicity marker enzyme activities, alkaline phos-
phatase (ALP), serum glutamic oxaloacetic transaminase
(SGOP), and serum glutamic pyruvic transaminase
(SGPT) in the serum were measured using standard pro-
tocols [20].
Statistical analysis
The statistical significance of differences between groups
was determined using an ANOVA with Student's t test.
Null-hypothesis probabilities of p < 0.05 were considered
significant. All values are expressed as means ± SD.
Results
Distribution of recombinant adeno-associated virus 
vectors in mouse tissue
The distribution of the rAAV-hAGA vector was assessed
by isolating genomic DNA and determining the viral
genome sequence in the liver, kidney, heart, spleen, and
brain of Fabry mice injected with 2 × 1012 particles of
rAAV 2/2-hAGA, 2 × 1011 particles of rAAV 2/8-hAGA,
or 2 × 1012 particles of each rAAV 2/8-hAGA vector. The
genomic dosage of the viral vector was identified at 6, 12,
and 24 weeks after tail-vein injection. Quantitative analy-
ses revealed a dose-dependent increase in the copy num-Choi et al. Journal of Biomedical Science 2010, 17:26
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ber of rAAV-hAGA in the liver (Fig. 1A) and kidney (Fig.
1B).
α-Gal A activities in Fabry mice treated with rAAV-AGA 
vector
The α-Gal A enzyme activity was determined in the liver,
kidney, heart, spleen, and brain of mice at 6, 12, and 24
weeks after injection of rAAV-hAGA via the tail vein
(Table 1). The average α-Gal A enzyme activity in the
liver of wild-type mice was 75.7 ± 29.3 nmol/mg protein.
Fabry mice injected with 2 × 1011 particles of rAAV 2/8-
hAGA and 2 × 1012 particles of rAAV 2/8-hAGA vectors
showed α-Gal A activities of 1,861.4 ± 45.2 nmol/mg pro-
tein and 2,137.5 ± 80.9 nmol/mg protein, which were 24
times and 30 times that of wild-type mice at 6 weeks after
treatment, respectively. α-Gal A enzyme activities of
423.2 ± 24.5 nmol/mg protein and 1,267.6 ± 30.8 nmol/
mg protein were also observed in the kidney and were 7
and 20 times that of the wild-type mice at 6 weeks after
treatment. In the heart, spleen, and brain, the α-Gal A
activity was significantly higher in treated Fabry mice
than in wild-type mice. At 12 and 24 weeks after treat-
ment, the α-Gal A enzyme activities were still signifi-
cantly higher in the tissues of treated Fabry mice than of
wild-type mice. The α-Gal A activities in the liver, kidney,
and spleen were maintained for up to 60 weeks postinjec-
tion. These results were compared with those of Fabry
mice that received ERT. The α-Gal A enzyme activity in
the mice treated with 2 × 1012 particles of rAAV 2/8-
hAGA was significantly higher than that in the Fabry
mice that received ERT. These results demonstrated that
the rAAV 2/8-hAGA vector was efficiently expressed in
liver and kidney and that it produced high levels of α-
Gal A.
Gb3 levels in Fabry mice treated with rAAV-hAGA vector
The levels of Gb3 in the liver, kidney, heart, spleen, and
brain of treated Fabry mice were determined at 6, 12, and
24 weeks after injection (Table 2). After the injection of 2
× 1011 particles of rAAV 2/8-hAGA vector, there was
decrease in the Gb3 level in the liver, kidney, spleen, and
heart at 6 weeks, whereas the Gb3 content in the brain
was reduced moderately after 24 weeks. The Gb3 levels in
the tissues were dramatically decreased after injection of
2 × 1012 particles of rAAV 2/8-hAGA vector. However,
Gb3 reaccumulated in the kidney and brain at 24 weeks
after the injection.
α-Gal A expression in the liver and kidney of the Fabry mice
The liver α-Gal A content was significantly higher in the
mice treated with 2 × 1012 particles of rAAV 2/8-hAGA
vector than in the mice treated with 2 × 1012 particles of
rAAV 2/2-hAGA vector or 2 × 1011 particles of rAAV 2/8-
hAGA vector. The α-Gal A protein levels in the liver
showed no significant changes at the various time points
(Fig. 2A). The kidney α-Gal A expression levels in the
mice treated with 2 × 1012 particles of rAAV 2/8-hAGA
vector were the highest (Fig. 2B). However, the expression
level was not much different than that in the mice treated
with 2 × 1011 particles of rAAV 2/8-hAGA vector. The
expression of α-Gal A in the kidney of mice treated with 2
× 1012 particles of rAAV 2/2-hAGA vector was almost
undetectable. These results suggest that differences in the
viral expression serotype yield different dose titers.
Liver function test
Liver toxicity was evaluated at 1 week and 6 weeks after
tail-vein administration of the rAAV 2/8 vector by mea-
suring ALP, SGPT, and SGOT levels. At 1 week after
treatment, mean ALP levels in the untreated Fabry mice
Figure 1 PCR analysis of transduced α-Gal A gene in Fabry mice. DNA was extracted from the organs of Fabry mice 6, 12, and 24 weeks after vector 
injection and analyzed by PCR. rAAV-hAGA, whereas the 1.4-kb fragment corresponds to the mouse genomic α-Gal A gene. The distribution was iden-
tified in liver (A) and kidney (B) at 6, 12, and 24 weeks after treatment.Choi et al. Journal of Biomedical Science 2010, 17:26
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and Fabry mice treated with 2 × 1012 particles of rAAV
vector were 28 U/L and 30 U/L, respectively. Mean SGOP
levels in the untreated Fabry mice were 92 U/L and 102
U/L in the treated Fabry mice. The serum ALP, SGOP,
and SGPT levels were not significantly changed at 6
weeks after the treatment.
Immunohistochemistry of α-Gal A in the kidney
The kidneys of wild-type mice were strongly labeled with
α-Gal A, and most staining was observed in tubular epi-
thelial cells (Fig. 3A). Glomerular cells including podo-
cytes and mesangial cells did not express α-Gal A at
detectable levels. However, α-Gal A immunoreactivity
was not evident in the Fabry mice (Fig. 3B). The tubules
of the glomerulus showed a strong staining pattern and
virtually every cell in the vessel wall labeled positive for α-
Gal A in the mice that had ERT and mice that had gene
therapy (Fig. 3C and 3D).
Gb3 staining in the kidneys of Fabry mice
Gb3 immunoreactivity was not observed in wild-type
mice (Fig. 4A). However Gb3 immunoreactivity strongly
appeared in the kidneys of Fabry mice (Fig. 4B). As
expected, Gb3 staining in the kidneys of Fabry mice
treated with enzyme replacement showed a mild amelio-
ration of Gb3 deposition in the glomerulus and tubules
(Fig. 4C), whereas no Gb3 was detected in the kidneys of
mice treated with gene therapy (Fig. 4D). The Gb3 immu-
nostaining signal in the Fabry mice significantly
decreased after treatment with either ERT or gene ther-
apy.
Ultrastructural study of the kidneys of Fabry mice
The ultrastructure of the mouse renal proximal tubules
was observed by electron microscopy. Gene therapy more
effectively removed lipid accumulation from proximal
Table 1: α-Gal A enzyme activity in the tissues of mice after tail vein administration of rAAV2/8-hAGA vector
Mice group Weeks after 
injection
Enzyme activity (nmol/h/mg protein)
Liver Kidney Spleen Heart Brain
Wild-type 
mice
75.7 ± 29.3 63.6 ± 20.5 189.7 ± 23.2 55.1 ± 7.18 111.8 ± 12.2
Fabry mice 1.2 ± 0.13 1.3 ± 0.47 4.3 ± 0.97 0.3 ± 0.16 1.4 ± 0.26
Treated mice
2 × 1011 a
6 1861.4 ± 
45.2**
423.2 ± 
24.5***
2036.1 ± 
47.0**
1837.2 ± 
40.1***
106.9 ± 8.1
12 186.1 ± 65.7* 161.7 ± 62.1* 1059.9 ± 
423.7**
1263.0 ± 
152.0**
66.3 ± 3.2
24 90.8 ± 42.7 19.4 ± 0.5 305.9 ± 14.1 31.4 ± 4.04* 10.0 ± 2.1
Treated mice
2 × 1012 b
6 2137.5 ± 
80.9***
1267.6 ± 
30.8***
6413.8 ± 
336.9***
4614.7 ± 
179.8***
310.3 ± 7.5***
12 1062.3 ± 
189.8***
600.6 ± 
392.2***
4276.1 ± 
214.1***
1297.9 ± 
746.0***
263.0 ± 87.2*
24 734.4 ± 
79.2***
270.1 ± 4.5** 1216.3 ± 
44.8***
601.6 ± 
13.2***
257.0 ± 18.6*
48 366.2 ± 
22.8***
127.0 ± 14.7** 451.0 ± 9.7** 81.1 ± 10.3** 247.2 ± 30.3*
60 245.5 ± 
95.0***
64.0 ± 23.7 335.7 ± 11.8** 23.2 ± 1.3 37.7 ± 9.2
Treated mice
ERTc
6 84.3 ± 15.4* 30.7 ± 7.5 96.7 ± 26.5 67.18 ± 4.6* 142.4 ± 37.6**
Data are presented as average ± SD, amice treated with 2 × 1011: rAAV2/8-hAGA (2 × 1011 particles/mouse). b mice treated with 2 × 1012: rAAV2/
8-hAGA (2 × 1012 particles/mouse), c ERT treated mice: 1.0 mg/kg once a week for 6 consecutive weeks. * p < 0.05, ** p < 0.01, and *** p < 0.001 
vs. wild mice (paired t test), n = 3.Choi et al. Journal of Biomedical Science 2010, 17:26
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tubules than ERT, shown as a round, dark, laminated
intracytoplasmic body (Fig. 5A-D).
The podocytes of wild-type mice, Fabry mice, mice
treated with ERT, and mice treated with rAAV-hAGA
gene transfer are shown in Fig. 6. In the podocytes of the
Fabry mice, foot process fusion and a storage process
occurred and Gb3 accumulated, while filtration slits
formed multivesicular bodies and degraded, and the slits
diaphragm formed a complex (Fig. 6B). When such phe-
nomena occur, proteinuria and glomerulosclerosis can
develop. In addition, in the inner capillaries, the pores of
endothelial cells underwent fenestration and formed an
inclusion. The mesangial cells became complex and
began to resemble an inflammatory state. In the Fabry
mice treated with ERT, foot process fusions appeared in a
few glomerular podocytes (Fig. 6C), suggesting that pod-
ocyte injury recovered partially by ERT. The glomerular
podocyte of mice kidney treated with gene therapy
appeared completely normal (Fig. 6D).
Discussion
Conventional ERT using recombinant α-Gal A is an effec-
tive treatment for Fabry disease. In ERT for Fabry disease,
α-Gal A injected intravenously decreases Gb3 accumula-
tion [5-9].
In this study, we sought to determine whether the use
of a pseudotyped rAAV 2/8 vector, which purportedly
produces more efficient hepatic transduction [14,21],
would produce higher levels of α-Gal A expression and
consequently greater affects on the pathology in the
affected kidneys of Fabry mice. These studies proved that
h i g h e r  l e v e l s  o f  e n z y m e  p r o d u c t i o n  c o u l d  b e  a c h i ev e d
with a recombinant AAV2/8 vector than with an AAV2/2
vector, and that this led to significantly greater and more
rapid reduction of lysosomal storage of Gb3 in the kid-
neys of treated Fabry mice. Thus, whereas the kidneys
appear to be somewhat refractory to treatment, this limi-
tation is overcome, at least in part, by exposure to higher
levels of the enzyme [22,23]. Gene therapy with a pseudo-
typed rAAV2/8 vector has the unique potential to provide
a safe and long-lasting treatment to overcome the current
requirement for chronic frequent enzyme infusions and
to treat diseases of the renal endothelial cell. In this study,
long-term expression of α-Gal A was observed in the
mouse model of Fabry disease for up to 60 weeks after
treatment. These findings may be the result of a success-
Table 2: Gb3 levels in mouse tissues after tail vein administration of rAAV2/8-hAGA vector
Mice group Weeks after 
injection
Gb3 levels (nmol/mg protein)
Liver Kidney Spleen Heart Brain
Untreated 
Fabry
mice
2.498 ± 0.261 7.466 ± 0.743 20.665 ± 5.999 7.179 ± 1.939 2.079 ± 1.099
Treated mice
2 × 1011a
6 0.001 ± 0.001 0.032 ± 0.018 0.014 ± 0.007 0.003 ± 0.001 0.139 ± 0.022
12 0.010 ± 0.001 0.832 ± 0.108 1.098 ± 0.129 0.058 ± 0.047 0.520 ± 0.192
24 0.015 ± 0.001 1.948 ± 1.487 1.392 ± 0.215 0.054 ± 0.040 1.832 ± 0.299
Treated mice
2 × 1012b
6 0.005 ± 0.002 0.019 ± 0.007 0.013 ± 0.006 0.002 ± 0.001 0.092 ± 0.043
12 0.007 ± 0.004 0.640 ± 0.349 0.197 ± 0.054 0.019 ± 0.076 0.325 ± 0.146
24 0.019 ± 0.020 0.359 ± 0.011 0.695 ± 0.252 0.040 ± 0.019 1.267 ± 0.210
48 0.046 ± 0.001 0.008 ± 0.001 0.732 ± 0.026 0.069 ± 0.108 1.434 ± 0.097
60 0.092 ± 0.001 0.023 ± 0.071 0.969 ± 0.049 0.502 ± 0.901 1.640 ± 0.127
Treated mice
ERTc
6 0.002 ± 0.001 0.263 ± 0.062 0.015 ± 0.005 0.003 ± 0.001 0.098 ± 0.025
Wild-type 
mice
0.036 ± 0.013 0.150 ± 0.013 0.252 ± 0.058 0.036 ± 0.0087 0.025 ± 0.011
Data present as average ± SD, a mice treated with 2 × 1011: rAAV2/8-hAGA (2 × 1011 particles/mouse), b mice treated with 2 × 1012: rAAV2/8-
hAGA (2 × 1012 particles/mouse), n = 3. cERT treated mice: 1.0 mg/kg once a week for 6 consecutive weeks.Choi et al. Journal of Biomedical Science 2010, 17:26
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ful transgenic effect in the establishment of rAAV2/8-
hAGA. The rAAV2/8-hAGA transfer via mice tail veins
did not result in liver toxicity. A progressive decline in α-
Gal A activity was observed in the Fabry mice during the
period examined [12]. However, the residual enzyme
activity at 60 weeks after treatment in the Fabry mice
treated with rAAV2/8-hAGA appeared to be sufficient to
maintain to correct the Gb3 levels in the tissues. A pro-
gressive decline in the transgene expression may reflect
the characteristics of the rAAV vectors, which exist pri-
marily as extrachromosomal elements [24,25], or devel-
opment of an immune response to human α-Gal A
protein in α-Gal A null mice [12,26].
Previous studies indicated the overexpression of human
α-galactosidase A, as well as the existence of the α-Gal A
gene in the responsible organs [27-29]. The α-Gal A
expression is observed in all tubular segments and inter-
stitial cells of normal kidneys [29]. A previous study indi-
cated that although the glycosphingolipids may
accumulate in endothelial, glomerular, and tubular cells
in Fabry disease, glomeruli and endothelial cells did not
express the enzyme after ERT [29]. The immunohis-
tochemical analysis in this present study clarified that α-
Gal A expression is observed in glomeruli of the kidneys
of Fabry mice after high-dose gene therapy. In accordance
with a previous study [29], no α-Gal A was detected in the
glomeruli after ERT. The α-Gal A protein expressed in
glomeruli might arise from protein secreted by the liver, a
depot organ in Fabry mice for the delivery of recombi-
nant enzyme, rather than direct transduction of rAAV 2/
8 [12,14,30].
T he ultrastructure of mice kidneys was examined by
electron microscopy. Proximal tubules (Fig. 6) in mice
treated by gene therapy more effectively removed lipid
accumulation than those in mice treated by ERT. Glomer-
ular changes, including segmental sclerosis, focal foot
process fusions, and endothelial microlesions, were
detected by transmission electron microscopy. Proteinu-
Figure 2 Western blot analysis of α-galactosidase A expression in liver and kidney at 6, 12, and 24 weeks after treatment in Fabry mice. Liver 
and kidney tissue lysates were immunoblotted using anti-α-galactosidase A antibodies. α-Gal A protein expression in liver and kidney at 6, 12, and 24 
weeks after injection is demonstrated in (A), and levels of α-Gal A in liver (B) and kidney (C) were quantified using a bioimaging analyzer. Experiments 
were repeated approximately three to five times using each sample. Values are expressed as means ± SD (n = 3 or 4). *p < 0.05, **p < 0.01 and ***p < 
0.001 vs. GAPDH using Student's t test. Black bar: 6 weeks after injection (n = 5), gray bar: 12 weeks after injection (n = 3), white bar: 24 weeks after 
injection (n = 3).Choi et al. Journal of Biomedical Science 2010, 17:26
http://www.jbiomedsci.com/content/17/1/26
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ria has been described as the first sign of renal functional
impairment in Fabry disease [31-33]. Although not com-
pletely understood, it seems likely that patients with
Fabry disease have a predisposition to inflammatory or
immune-mediated renal disease related to the toxic accu-
mulation of glycosphingolipids and exposure of the glom-
e r u l a r  b a s e m e n t  w i t h  c o n s e q u e n t  s y n e c h i a e  f o r m a t i o n
[22,23,34]. This accumulation is seen in patients at renal
biopsy, with no other findings that suggested alternative
causes of nephrotic syndrome, although the foot process
fusion seen on electron microscopy can also be seen with
minimal change in disease. Clinical studies of ERT for
Fabry disease have demonstrated different degrees of
clearance of glycosphingolipid deposits. This clearance
results in improved glomerular architecture over several
months of therapy, but has a limited effect on proteinuria
[15,35]. The rate of reaccumulation of Gb3 after injection
of 2 × 1012 viral particles per mouse was assessed to
determine the dose frequency needed to maintain
reduced Gb3 levels. The accumulated hepatic Gb3 was
Figure 5 Gb3 clearance from proximal renal tubules of kidney of rAAV 2/8-treated Fabry mice. (A) Wild-type mice, (B) Fabry mice (at 24 weeks), 
(C) 6 weeks after ERT, and (D) 6 weeks after gene therapy (2 × 1012 rAAV2/8-hAGA). The mice were killed 6 weeks after injection and kidney tissue was 
examined by electron microscopy. Gb3 containing myeloid bodies were recognized in proximal tubules (×8000).
Figure 4 Immunohistochemistry of CD77/Gb3 in the kidney of 
Fabry mice. (A) Wild-type mice unstained, (B) staining appeared in 
glomeruli and tubules of untreated Fabry mice, (C) stained tubules and 
glomeruli in Fabry mice treated with ERT, (D) No detection after 6 
weeks in Fabry mice injected with 2 × 1012 particles of rAAV2/8-hAGA 
(×200).
Figure 3 α-Gal A immunostaining in the kidney. Kidney sections 
were stained with peroxidase-conjugated rabbit anti-human α-galac-
tosidase A shown as browning to plasmic staining. (A) Wild-type mice, 
(B) untreated Fabry mice, (C) Fabry mice treated with ERT, (D) Fabry 
mice treated with gene therapy (2 × 1012 particles of rAAV2/8-hAGA) 
(×200).Choi et al. Journal of Biomedical Science 2010, 17:26
http://www.jbiomedsci.com/content/17/1/26
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rapidly cleared and remained at undetectable levels for 6
weeks, whereas the spleen and cardiac Gb3 concentra-
tions were maximally decreased at 6 and 12 weeks postin-
jection, respectively, before both began to reaccumulate.
This finding suggests that a dose of 2 × 1012 viral particles
per mouse could both deplete the accumulated Gb3 and
prevent its reaccumulation. The biochemical demonstra-
tion of depletion of accumulated tissue Gb3 is consistent
with the ultrastructural findings of fewer, smaller, or less
dense lysosomes in the tissues of treated mice. Markedly
decreased lysosomal glycolipid storage was observed in
podocytes and tubules of the kidneys. These findings sug-
gest that α-Gal A is readily endocytosed into endosomes
for subsequent processing by lysosomes containing the
substrate.
There are several issues to overcome before rAAV vec-
tor-mediated gene therapy can be used clinically. Efficient
and versatile large-scale AAV vector-production systems
are needed for clinical application of this vector [36]. The
host immune response remains of concern [25]. Although
AAV vectors are unlikely to cause insertional mutagene-
sis, the issue remains of concern; however, the recombi-
nant AAV genome does not integrate site-specifically into
the chromosome [24,25]. Despite these concerns, AAV
remains a promising delivery system for gene therapy. For
the mouse model of Fabry disease, a high dose of rAAV-
mediated α-Gal A gene transfer achieved a greater effi-
cacy than did ERT. A single injection of rAAV2/8-hAGA
in Fabry mice produced long-term efficacy and caused no
apparent hepatic damage. Immunohistochemistry and
electron microscopy studies showed clear evidence of
effective α-Gal A expression and Gb3 clearance in the
kidney of Fabry mice given gene therapy. Although it is
difficult to conclude which system is more effective for
treating patients with Fabry disease, AAV-mediated gene
therapy can be an effective therapeutic strategy.
Conclusions
These studies have shown the efficacy of rAAV 2/8-
hAGA-mediated gene therapy for both biochemical and
functional deficits in the Fabry disease mouse model.
Recombinant AAV 2/8-hAGA-mediated expression pro-
duced good efficacy that was comparable to that of ERT,
especially in the kidney.
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